Inspire Medical Systems Sets Strategic Update for J.P. Morgan Healthcare Conference
Minneapolis, Monday, 29 December 2025.
Inspire Medical Systems (NYSE: INSP) is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, offering a pivotal update for the investment community. This presentation comes at a critical juncture for the Minneapolis-based medical technology firm. While Inspire recently reported robust Q3 2025 financials—including a 10% revenue increase to $224.5 million and raised full-year guidance—the company is simultaneously navigating shareholder litigation regarding its Inspire V launch. With the stock trading around $95.47 as of late December 2025, investors will be keenly focused on management’s strategy to sustain growth in the obstructive sleep apnea market while addressing these operational and legal headwinds.
Presentation Details and Webcast Availability
The management team is set to take the stage on Monday, January 12, 2026, at 12:45 p.m. Eastern Time [1]. For stakeholders unable to attend the conference in person, Inspire Medical Systems has arranged for a live webcast of the presentation, which will remain available for replay in the Event Archive section of their investor relations website for two weeks following the event [1]. This appearance offers a timely opportunity for the company to articulate its forward-looking strategy directly to institutional investors, particularly as it prepares to release its next earnings report scheduled for February 9, 2026 [3].
Operational Growth Amidst Market Scrutiny
Financially, Inspire Medical Systems has demonstrated resilience in its core operations. In the third quarter of 2025, the company reported revenue of $224.5 million, representing a 10% increase year-over-year [3]. Profitability metrics also showed strength; the company achieved earnings per share (EPS) of $0.38, significantly outperforming market forecasts which had anticipated a loss of -$0.20 [3]. Furthermore, operational efficiency gains were evident as the gross margin expanded by 1.7 percentage points to 85.8% compared to the previous year [3]. Consequently, management raised its full-year 2025 EPS guidance to a range of $0.90 to $1.00, up from the prior estimate of $0.40 to $0.50 [3].
Litigation and Institutional Shifts
A significant portion of the current market volatility can be attributed to legal challenges surrounding the company’s product pipeline. Inspire Medical Systems is currently facing securities suits related to a stock drop linked to the “Inspire V” launch failure [2]. Notably, court filings confirm that the Indiana Public Retirement System filed a lawsuit against the company on December 22, 2025, in the New York Southern District Court under the Securities Exchange Act [4]. These legal headwinds have coincided with notable shifts in institutional ownership. Voya Investment Management LLC, for instance, reduced its position by 79.9% during the third quarter, selling 142,493 shares [2].